This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To assess the overall risk of stroke, specifically ischemic stroke, associated with tamoxifen use by performing a meta-analysis of data reported in breast cancer trials.
Background: Tamoxifen increases the risk of venous thromboembolism in women with breast cancer, but its relationship to stroke risk is uncertain.
Methods: A systematic review of randomized controlled trials of tamoxifen for breast cancer management and prevention published since 1980 was performed using MEDLINE. The summary odds ratio (OR) and 95% CI were calculated using the Mantel–Haenszel method, followed by a statistical test for heterogeneity.
Results: Nine trials met the inclusion criteria, and six trials specified ischemic stroke outcomes. The Mantel–Haenszel summary OR was 1.82 (95% CI, 1.41 to 2.36) for ischemic stroke and 1.40 (1.14 to 1.72) for any stroke. The χ2 heterogeneity test was 6.0 (p > 0.1) for ischemic stroke and 16.1 (p < 0.05) for any stroke. The random-effects summary OR of Der Simonian and Laird for any stroke was 1.29 (0.92 to 1.81). During a mean follow-up period of 4.9 years, the frequency of ischemic stroke was 0.71% with tamoxifen vs 0.39% for controls (absolute increased risk, 0.32%; number needed to harm [NNH], 313).
Conclusions: Women with breast cancer who were treated with tamoxifen had an 82% increased risk of ischemic stroke and a 29% increased risk of any stroke, but the absolute risk is small. Further studies assessing prespecified cerebrovascular outcomes are ongoing and will further clarify the risk of stroke associated with tamoxifen use.
- Received May 6, 2004.
- Accepted June 3, 2004.
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.